Back to Lung Cancer

Lung Cancer: patient access summary

A printable summary of what is publicly known about access to treatment for Lung Cancer in Australia: PBS subsidy, Australian trial recruitment, and where the gaps are. Nothing here is new information; it is the same reviewed data as the Lung Cancer page, laid out to print. Not medical advice.

Access in Australia

Can you access treatment for Lung Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Clinical trial activity

Counted from the nightly snapshot of the full public trial registry data Voxsanity holds for Lung Cancer.
Trials on record 5,276 This is every trial tagged to this condition at any stage whose registry record agrees it is for this condition, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
Recruiting now 994 This counts only trials whose registry status is "Recruiting" and whose registry record agrees they are for this condition. Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
Recruiting with an AU site 56 This counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
Phase 3 trials 111 This counts trials counted under "Recruiting now" that are at Phase 3.

The trial catalogue is checked nightly, but individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Trials recruiting at Australian sites

Why this list is shorter than "Trials on record". Of the 5,276 trials on record for Lung Cancer, 1,394 are listed on Voxsanity. The list carries trials we can show a plain English summary for: every trial open or about to open to new participants, plus concluded trials that have published their results. The great majority of the difference is research that finished without publishing a results summary, so there is nothing to read and nothing to join. A smaller part is trials that are open now but whose plain English summary has not been written yet. Nothing is being withheld: the larger figure counts research history, this list counts what is useful to read today.

56 of them are recruiting and list at least one Australian site. A listed site is not proof it is enrolling today; confirm with the trial's own contacts before relying on it.

Registry ID Phase Sponsor Status
NCT02468024 Phase 3 University of Texas Southwestern Medical Center Recruiting
NCT04585750 Phase 2 PMV Pharmaceuticals, Inc Recruiting
NCT04613596 Phase 3 Mirati Therapeutics Inc. Recruiting
NCT04676828 Not Applicable University of Aarhus Recruiting
NCT04928846 Phase 3 AbbVie Recruiting
NCT05030207 Not Applicable University of Sydney Recruiting
NCT05086692 Phase 2 Medicenna Therapeutics, Inc. Recruiting
NCT05142189 Phase 1 BioNTech SE Recruiting
NCT05267626 Phase 2 Aulos Bioscience, Inc. Recruiting
NCT05706129 Phase 2 Lumara Bio Oncologics GmbH Recruiting
NCT05789082 Phase 2 Hoffmann-La Roche Recruiting
NCT05920356 Phase 3 Amgen Recruiting
NCT05967689 Phase 2 Taiho Oncology, Inc. Recruiting
NCT06119581 Phase 3 Eli Lilly and Company Recruiting
NCT06127654 Phase 3 University of Sydney Recruiting
NCT06159660 Not Applicable University of Sydney Recruiting
NCT06170788 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06172478 Phase 2 Daiichi Sankyo Recruiting
NCT06242470 Phase 1 MacroGenics Recruiting
NCT06337084 Phase 1 Monopar Therapeutics Recruiting
NCT06343402 Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology The... Recruiting
NCT06345729 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06357533 Phase 3 AstraZeneca Recruiting
NCT06452277 Phase 3 Bayer Recruiting
NCT06465069 Phase 1 Eli Lilly and Company Recruiting
NCT06515990 Phase 1 Doma Biopharmaceutical(Suzhou)Co., Ltd. Recruiting
NCT06613009 Phase 1 Innovent Biologics (Suzhou) Co. Ltd. Recruiting
NCT06617169 Phase 1 Monopar Therapeutics Recruiting
NCT06623422 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT06625775 Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology The... Recruiting
NCT06692738 Phase 3 AstraZeneca Recruiting
NCT06706076 Phase 2 BlossomHill Therapeutics Recruiting
NCT06712316 Phase 3 BioNTech SE Recruiting
NCT06712355 Phase 3 BioNTech SE Recruiting
NCT06716437 Not Applicable University of Melbourne Recruiting
NCT06855771 Phase 2 Bristol-Myers Squibb Recruiting
NCT06868277 Phase 3 AstraZeneca Recruiting
NCT06875310 Phase 3 Mirati Therapeutics Inc. Recruiting
NCT06881784 Phase 3 Revolution Medicines, Inc. Recruiting
NCT06905197 Phase 1 Dizal Pharmaceuticals Recruiting
NCT06910657 Phase 1 ViroMissile, Inc. Recruiting
NCT07005102 Phase 3 AbbVie Recruiting
NCT07005128 Phase 3 Amgen Recruiting
NCT07063745 Phase 3 Bristol-Myers Squibb Recruiting
NCT07099898 Phase 3 GlaxoSmithKline Recruiting
NCT07144280 Phase 3 Pfizer Recruiting
NCT07174583 Phase 2 IDEAYA Biosciences Recruiting
NCT07185997 Phase 3 ArriVent BioPharma, Inc. Recruiting
NCT07226999 Phase 3 Pfizer Recruiting
NCT07288177 Phase 2 Genmab Recruiting
NCT07341737 Phase 2 Second Life Therapeutics Recruiting
NCT07361497 Phase 3 Bristol-Myers Squibb Recruiting
NCT07472517 Phase 3 Boehringer Ingelheim Recruiting
NCT07513376 Phase 3 Merck Sharp & Dohme LLC Recruiting
NCT07660055 Phase 1 Novartis Pharmaceuticals Recruiting
NCT07680764 Phase 2 Bristol-Myers Squibb Recruiting

Full eligibility for each trial is at voxsanity.com.au/trials/<registry ID>/, and on the registry itself: clinicaltrials.gov, or isrctn.com for an ISRCTN ID.

PBS-subsidised medicines

Updated nightly, except PBS listing data, which is updated monthly because the PBS publishes a new Schedule once a month.

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. The Government price column is the PBS-determined price the Government pays the pharmacy for the item — it is not what you pay at the counter. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest. Confirm the current amount with your pharmacist.

Medicine Brand(s) Listed for Government pricenot what you pay Authority
Afatinib Giotrif non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$2587.8 Authority required
Alectinib Alecensa non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$6320.43 Authority required
Brigatinib Alunbrig non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$1580.11 Authority required
Ceritinib Zykadia non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$6771.89 Authority required
Crizotinib Xalkori non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$6433.3 Authority required
Entrectinib Rozlytrek non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$6771.89 Authority required
Erlotinib Erlotinib Sandoz non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$104.59 Authority required
Gefitinib Cipla Gefitinib non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$468.02 Authority required
Lorlatinib Lorviqua non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$6272.46 Authority required
Osimertinib Tagrisso non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$7419.5 Authority required
Repotrectinib Augtyro non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$7528.28 Authority required
Tepotinib Tepmetko non-small cell lung cancer (NSCLC) Stage IIIB (locally advanced) or Stage IV (metastatic) AU$8942.2 Streamlined authority
Atezolizumab Tecentriq, Tecentriq SC non-small cell lung cancer (NSCLC) Stage IV (metastatic) AU$4723.15 Streamlined authority
Cemiplimab Libtayo non-small cell lung cancer (NSCLC) Stage IV (metastatic) AU$7290 Streamlined authority
Dabrafenib Tafinlar non-small cell lung cancer (NSCLC) Stage IV (metastatic) AU$4663.49 Streamlined authority
Pembrolizumab Keytruda non-small cell lung cancer (NSCLC) Stage IV (metastatic) AU$3632.56 Streamlined authority
Trametinib Mekinist non-small cell lung cancer (NSCLC) Stage IV (metastatic) AU$1748.81 Streamlined authority
Atezolizumab Tecentriq, Tecentriq SC non-small cell lung cancer Locally advanced or metastatic AU$4723.15 Streamlined authority
Selpercatinib Retevmo non-small cell lung cancer Locally advanced or metastatic AU$1975 Streamlined authority
Vinorelbine Velabine non-small cell lung cancer Locally advanced or metastatic AU$38.18 Authority required
Alectinib Alecensa non-small cell lung cancer (NSCLC) AU$6320.43 Authority required
Osimertinib Tagrisso non-small cell lung cancer (NSCLC) AU$7419.5 Authority required
Atezolizumab Tecentriq, Tecentriq SC small cell lung cancer Extensive-stage AU$4723.15 Streamlined authority
Durvalumab Imfinzi small cell lung cancer Extensive-stage AU$860.99 Streamlined authority
Osimertinib Tagrisso non-small cell lung cancer Stage IB, II or IIIA AU$7419.5 Authority required
Atezolizumab Tecentriq, Tecentriq SC non-small cell lung cancer (NSCLC) Resected early stage (Stage II to IIIA) AU$4723.15 Streamlined authority
Nivolumab Opdivo Resectable non-small cell lung cancer (NSCLC) AU$1972.83 Streamlined authority
Durvalumab Imfinzi small cell lung cancer Limited-stage AU$860.99 Streamlined authority
Durvalumab Imfinzi Stage III non-small cell lung cancer Unresectable AU$860.99 Streamlined authority
Amivantamab Rybrevant Stage IIIB/ IIIC (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) AU$1484 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

What this summary does not cover

  • Australian registration dates. Voxsanity holds no TGA registration record for any medicine, so no Australian registration date appears here or anywhere on this site. The TGA's own Australian Register of Therapeutic Goods (tga.gov.au/resources/artg) is the authoritative place to check. Where a medicine is on the PBS it must already be registered for supply in Australia, because a PBS listing cannot happen before that: that is read from the PBS, not from the TGA.
  • Access outside the PBS and outside a trial. Where a medicine is not registered or not available through a trial, the TGA Special Access Scheme may allow a doctor to apply for access for an individual patient. A plain English explainer is at voxsanity.com.au/sas-navigator/.
  • Whether any of it is appropriate. Nothing on this sheet is a recommendation. A medicine being subsidised, or a trial recruiting nearby, says nothing about whether either suits a particular person. That is a clinical judgement this sheet cannot make.

Not medical advice. Voxsanity republishes public government health data in plain English and does not provide medical advice. Always consult a qualified health professional before making any health decision. Trial status should be verified directly with the trial site. Sources: ClinicalTrials.gov and other public trial registries, and the Pharmaceutical Benefits Scheme.